Global COPD Drugs Market to expand with over 2% CAGR through 2023

November 11, 2019


According to the latest study titled ‘Global COPD Drugs Market: Analysis By Drug Type (Combination Therapy, Anticholinergics, Beta-Agonist, Inhaled Corticosteroids, Others), Pipeline Drugs, By Region, By Country (2019 Edition)- Forecast to 2023’ available at MarketStudyReport.com, the global COPD drugs market is estimated to grow with a CAGR of 2.47% through the year 2023.
 

Chronic obstructive pulmonary disease (COPD) includes lung-related diseases in which the patient finds it difficult to breathe due to damage of airways and air sacs. Rising level of pollution leading to growing prevalence of lung related disorders, increasing availability of new combination therapy drugs, and advancements in pharmaceutical sector are the key factors driving the growth of COPD drugs market.
 

Moreover, alertness and responsiveness towards COPD, changing lifestyle with smoking as regular activity, along with increasing medical expenditure and initiatives taken by government towards improving healthcare infrastructure will continue to augment the industry trends.
 

The study encompasses details about segmental shares, alongside the recommended strategies adopted by manufacturers to expand their market footprint. It also provides information about the challenges, drivers, trends, and restraints impacting COPD drugs market growth.
 

Based on drug type, COPD drugs market is segmented into anticholinergics, inhaled corticosteroids, combination therapy, beta-agonist, and other COPD drugs. As per the report, the combination therapy segment is estimated to display prominence over the estimated time period.
 

Request sample copy of this Report@ https://www.marketstudyreport.com/request-a-sample/1689403/
 

Considering the geographical landscape, the global COPD drugs industry is fragmented into four major regions, namely, Europe, North America, Asia Pacific, and rest of the world, with key focus on countries, like, Canada, U.S., Germany, U.K, France, Italy, China, Japan, and India. Furthermore, North America was the leading region in COPD drugs market as of 2017, claims the report. The regional growth is credited to the expanding patient base and rising preference for prescribed branded drugs.
 

Some of the vendors that operate in COPD drugs market are AstraZeneca, GlaxoSmithKline, TEVA Pharmaceuticals, Boehringer-Ingelheim, Novartis, Chiesi Pharmaceuticals, Merck, Mylan, Cipla, Sunovion, and Vectura.


Frequently Asked Questions (FAQ) :

Factors such as growing prevalence of lung related disorders, increasing availability of new combination therapy drugs, and advancements in pharmaceutical sector are the key factors driving the growth of COPD drugs market. Moreover, awareness regarding COPD, high smoking prevalence, rising levels of pollution, along with rise in medical expenditure, as well as initiatives taken by government will continue to augment the industry trends.
The global COPD drugs market is estimated to grow with a CAGR of 2.47 % through 2023.
Based on drug type, the chronic obstructive pulmonary disease drugs market is segmented into combination therapy, anticholinergics, inhaled corticosteroids, beta-agonist, and other COPD drugs.
Companies that comprise the competative landscape of COPD drugs market are AstraZeneca, GlaxoSmithKline, TEVA Pharmaceuticals, Boehringer-Ingelheim, Novartis, Chiesi Pharmaceuticals, Merck, Mylan, Cipla, Sunovion, and Vectura.